Novartis Drops 99% Effective Malaria Drug—Here’s Why It’s A Historic Milestone!

Novartis recently announced its third-quarter 2025 financial results, highlighting a period of strategic growth and progress across multiple fronts. The company registered a 7% increase in net sales, alongside a mirrored 7% uplift in core operating income, maintaining its core margin at 39.3%. The results underscore Novartis’ ability to drive growth amidst challenges such as the loss of exclusivity (LOE) for key products like Entresto, Tasigna, and Promacta. Despite the impact of LOEs, the performance of Novartis’ priority brands, such as Kisqali, Kesimpta, and Pluvicto, has been strong, with double-digit growth in several cases. Kisqali, in particular, reported remarkable growth of 68% in Q3, fueled by its leadership in the CDK4/6 inhibitor market for breast cancer. The drug’s U.S. sales surged by 91%, with expansion being evident internationally as well. Similarly, Kesimpta saw a 44% increase in sales, primarily driven by its demand in the U.S. market.